Not-for-profit organisation Stand Up To Cancer (SU2C) has formed a strategic alliance with US-based Lustgarten Foundation to support research to improve outcomes in patients with pancreatic cancer.

The Pancreatic Cancer Collective, funded by the Lustgarten Foundation and Stand Up To Cancer, will accelerate research for pancreatic cancer patients who need more effective treatments. The initial funding commitment will be $25m.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The partnership will focus on new approaches such as artificial intelligence-based techniques, and aims to encourage pre-clinical development research to boost innovative and effective treatments for the cancer.

Lustgarten Foundation chief scientist David Tuveson said: “The Collective will utilise the breadth and expertise of existing SU2C-Lustgarten Foundation research teams and researchers to support new investigators coming into the field and expand the capacity for additional research.”

“The Collective will utilise the breadth and expertise of existing SU2C-Lustgarten Foundation research teams and researchers to support new investigators coming into the field and expand the capacity for additional research.”

SU2C will provide an additional $10m for research aimed at improving the treatment of multiple myeloma through early detection of precursor conditions, which do not cause symptoms.

Researchers will examine blood samples from about 50,000 people in the US and expect to identify approximately 3,000 with precursor conditions.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

These samples will be used to identify biomarkers and pinpoint those at high risk of disease progression.

The team also intends to develop therapies for multiple myeloma and high-risk smoldering multiple myeloma.

Researchers believe that gaining better insights into the molecular and immune factors associated with disease development, when combined with early detection, can aid the development of new strategies to prevent progression and improve survival.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact